Navigation Links
Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing
Date:12/4/2009

nd clearance from the FDA for Phase I trials in five other cancers. The Company is also conducting a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and uncertainties about whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company ass
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
2. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
3. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
4. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
5. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
6. Northwestern Memorial Transplant Program Initiates New Study
7. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
8. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
9. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
10. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
11. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Trial... -- MONT-SAINT-GUIBERT, Belgium, November 17, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... 2010 In response to an expressed need by ... facilitate the sharing and exchanging of data among PMP ... will be developing an interconnected communications hub for state ... nine months, will be made accessible to the states ...
Cached Medicine Technology:Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 2Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 3Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 4Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 5Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 6Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 7Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 8Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 9Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 10Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 11Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 12NABP Developing System to Link Prescription Monitoring Programs Across States to Facilitate Data Exchange 2
(Date:4/23/2014)... health benefits of probiotics, antioxidants and other nutritional compounds, ... chemical industry is getting in on the action. But ... so the industry is responding with clinical research to ... in Chemical & Engineering News (C&EN), the ... Melody M. Bomgardner, a senior editor at C&EN, writes ...
(Date:4/23/2014)... concerned about an increase in adolescents, marijuana use following ... of relief. According to a new study at Rhode ... from states with and without medical marijuana laws, legalizing ... adolescents. The study is published online in advance of ... , "Any time a state considers legalizing medical ...
(Date:4/23/2014)... the bottom of Alzheimer,s disease has been a ... controversies. In the latest crook in the research ... the interaction between proteins associated with the disease. ... ACS Chemical Neuroscience , could have important implications ... Krzysztof Nieznanski and colleagues explain that for years, ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... The International Communication Association will hold its 64th ... theme of the 2014 conference will explore what ... digital society. , Featuring over 2,300 academic papers ... scholars representing over 40 countries, the ICA conference ... the world. This year,s conference features sessions that ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... content talking to an imaginary friend rather than a real one ... such a pal can have a positive effect on children. ... in London also insists that imaginary friends are not a sign ... his or her age group, but a sign that your child ...
... drugs may give a man's performance in bed a boost, ... or their relationships . ,A survey of ... have poorer esteem, a weaker sense of masculinity and lower ... dysfunction (ED), including half who had tried drug treatment, and ...
... hope revived for women who feel less than that, after ... claim that stem cells found in the ubiquitous tummy fat ... this is so, it would be killing two birds with ... ,Christened Celution, the procedure involves injecting a 'supercharged' fat ...
... Dr. Endress and his colleagues found that the sizes ... buzz-pollinating bees . The male floral structures, anthers, release ... ,Unlike moths and butterflies that are often brilliantly ... flowers and the fruits they produce have brilliant colors ...
... increases a person's risk of colon cancer by 23 percent ... by a team of researchers from the University of Michigan ... Institute of Oncology in Spain, the CHS National Israeli Cancer ... including Stephen Gruber and Gad Rennert. ,As part ...
... treatments using their knowledge about an obesity drug, orlistat (Xenical ... the laboratory . ,The drug binds and interacts ... protein's function and causes cell death. ,The study ... and W. Todd Lowther at Wake Forest University School of ...
Cached Medicine News:Health News:Stem Cells In Belly Fat To Enhance Or Reconstruct Breasts 2Health News:Size and Position of Floral Anther Plays a Vital Role in Pollination 2Health News:Size and Position of Floral Anther Plays a Vital Role in Pollination 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: